MitchellASomervilleLWilliamsN, et al.Implanted intrathecal drug delivery systems may be associated with improved survival in patients with cancer. Br J Pain2024; 18: 110–119.
2.
SmithTJStaatsPSDeerT, et al.Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity. Survival J Clin Oncol2002; 20: 4040–4049.
3.
DuarteRCopleySNevittS, et al.Effectiveness and safety of intrathecal drug delivery systems for the management of cancer pain: a systematic review and meta-analysis. Neuromodulation2022; S1094-7159(22): 00563.
4.
MercadanteS. Devices or care for cancer pain management?Anesth Analg2020; 130: e151–e152.
5.
StearnsLMAbd-ElsayedAPerruchoudC, et al.Intrathecal drug delivery systems for cancer pain: an analysis of prospective, multicenter product surveillance registry. Anesth Analg2020; 130: 289–297.
6.
MercadanteSAdileCFerreraP, et al.When the game is hard, more complex weapons are needed. BMJ Support Palliat Care2022, bmjspcare-2021-003518.
7.
MercadanteSIntravaiaGVillariP, et al.Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain2007; 23: 793–798.
8.
MercadanteSPortenoyRK. Breakthrough cancer pain: twenty-five years of study. Pain2016; 157: 2657–2663.
9.
RauckRCherryDBoyerM, et al.Long-term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain. J Pain2003; 4: 441–447.
10.
MaKJinYWangL, et al.Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020; 161: 2502–2510.
11.
Letter to Editor. J Pain, 2005;5:138-139.
12.
MercadanteS. Intrathecal patient-controlled analgesia has nothing to do with breakthrough cancer pain. Pain2021; 162: 1586.
